Search company, investor...

Tiziana Life Sciences

Founded Year



Reverse Merger | IPO

Market Cap


About Tiziana Life Sciences

Tiziana Life Sciences is a UK biotechnology company focused on developing therapeutics and diagnostics for cancers and immune diseases.

Headquarters Location

55 Park Lane

London, England, W1K 1NA,

United Kingdom

Missing: Tiziana Life Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Tiziana Life Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Tiziana Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tiziana Life Sciences is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Tiziana Life Sciences Patents

Tiziana Life Sciences has filed 9 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Experimental cancer drugs
  • Antineoplastic drugs
patents chart

Application Date

Grant Date


Related Topics




Acute myeloid leukemia, Transcription factors, Experimental cancer drugs, Myeloid neoplasia, Orphan drugs


Application Date


Grant Date



Related Topics

Acute myeloid leukemia, Transcription factors, Experimental cancer drugs, Myeloid neoplasia, Orphan drugs



Latest Tiziana Life Sciences News

Optimum Expands its Team with Senior Investor Relations and Communications Hires Jonathan Edwards and Hana Malik

Feb 15, 2023

News provided by Share this article Share this article LONDON, Feb. 15, 2023 /PRNewswire/ -- Optimum Strategic Communications ("Optimum"), the specialist life sciences communications consultancy, today announces that it has hired Jonathan Edwards and Hana Malik, two highly experienced investor relations and communications professionals, to join as permanent members of its team. Edwards and Malik have joined Optimum as Account Directors and will be advising clients across its life sciences, healthcare and industrial biotechnology portfolio. Edwards has over 10 years' investor relations experience across energy and consumer sectors working in-house and in advisory businesses. He has a wealth of knowledge and expertise advising senior management teams and companies on refinancing activities, capital raises and M&A transactions. Malik joins from NASDAQ listed Tiziana Life Sciences, where she was responsible for Investor Relations and Business Development working closely with the senior management team, advising on IR and PR strategy. Whilst at Tiziana, Malik managed the Company's move from LSE AIM to NASDAQ. Prior to this Malik created and supported the IR/PR strategy for OKYO Pharma Ltd. Commenting on the appointments, Mary Clark, Chief Executive Officer of Optimum Strategic Communications, said: "We are delighted to welcome Jonathan and Hana to Optimum. Jonathan is a highly experienced professional which will be invaluable in advising and supporting our clients on their IR strategies. Hana has extensive experience in the life sciences and biotechnology sectors helping companies to communicate a compelling investment story. Her experience of working with both the LSE and NASDAQ indices will be very useful in preparing companies for listing in the US." Jonathan Edwards, Account Director at Optimum Strategic Communications commented: "After more than a decade working in Investor Relations, I am thrilled that the next step in my career is joining the incredibly experienced, talented and hardworking team at Optimum. The Company's clients are some of the world's most exciting businesses in the pharmaceuticals, biotech and healthcare space and it is a privilege to have the opportunity to be a part of, and contribute to, this exciting sector." Hana Malik, Account Director at Optimum Strategic Communications added: "Having worked in the life sciences and biotech industry for nearly a decade, I am very excited to be taking this next step in my career. Increasingly companies are looking to US public markets and my experience will be invaluable in helping them navigate this journey. I look forward to working with Optimum's interesting and innovative clients and helping them to achieve their business goals." About Optimum Strategic Communications Optimum Strategic Communications is an international healthcare communications firm which specialises in strategic investor relations, corporate and financial communications. Our senior healthcare specialists, based in London, Amsterdam, Stockholm, Zurich, and New York, are experienced and trusted advisors to some of the world's most exciting public and private companies, both large and small, across healthcare, life sciences and industrial biotechnology. Over the last 20 years we have worked with over 300 healthcare companies, advising them on financial communications and investor relations, including major corporate activities such as fundraising, IPOs, and M&A, as well as corporate reputation and crisis scenarios. We have an exceptional network of contacts across the international investment community in Europe and the US; contacts we have built and maintained over the last three decades. Our team includes ex-fund managers and analysts, scientists, as well as financial and corporate communications specialists. For more information, please visit . About Jonathan Edwards Jonathan has vast experience developing and communicating narratives that have covered an array of different scenarios and has supported and advised a wide range of senior management teams on best practice Investor Relations (IR) and Communication strategies. Jonathan began his career at HSBC shortly after graduating from the University of Liverpool with a business degree. He moved into IR in 2012 and began working within the energy sector at UK listed Petrofac. He has worked for both private and public companies across a variety of sectors, including energy, support services, retail and for an IR consultancy, where he advised a number of listed clients across a range of sectors on their IR and communication programmes. He is passionate about IR and supporting companies to tell their story to stakeholders. About Hana Malik Hana has worked in the Life Sciences and Biotechnology industry for eight years. Prior to joining Optimum, Hana served as the Investor Relations and Business Development Manager at Tiziana Life Sciences, where she supported the transition of Tiziana from LSE: AIM to NASDAQ. As part of her Business Development role, Hana engaged with big and small pharma. Hana also created and supported the IR/PR strategy for OKYO Pharma Ltd, an LSE Main Market listed company. She has worked with several private biotechnology companies, helping them to communicate corporate messaging and engaging with shareholders. Hana holds a MSc. in Biomedical and Molecular Sciences from Kings College, London, and a BEng. in Dental and Materials Sciences from Queen Mary, University of London. SOURCE Optimum Strategic Communications

Tiziana Life Sciences Frequently Asked Questions (FAQ)

  • When was Tiziana Life Sciences founded?

    Tiziana Life Sciences was founded in 2013.

  • Where is Tiziana Life Sciences's headquarters?

    Tiziana Life Sciences's headquarters is located at 55 Park Lane, London.

  • What is Tiziana Life Sciences's latest funding round?

    Tiziana Life Sciences's latest funding round is Reverse Merger.

  • Who are the investors of Tiziana Life Sciences?

    Investors of Tiziana Life Sciences include Alexander David Investments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.